Cancer research最新文献

{"title":"Abstract CT223: The building of a cancer vaccine trial platform: The NHS England Cancer Vaccine Launch Pad (CVLP)","authors":"Gareth Griffiths, Victoria Goss, Nicole Keyworth, Daniel Muller, Sam Wilding, Simon Crabb, Emily Shaw, Nicola Chapman-Hart, Max Shen, Patrick Ezeani, Gillian Rosenberg, Peter Johnson","doi":"10.1158/1538-7445.am2025-ct223","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-ct223","url":null,"abstract":"Background: The CVLP has been established to address the process for generating personalized vaccines at scale, by recruiting suitable patients and supporting accelerated tumor tissue processing. The CVLP is a collaborative project including NHS England, Genomics England, the Department of Health and Social Care, the Office for Life Sciences and the National Institute of Health and Care Research (NIHR) which is being delivered by the Cancer Research UK Southampton Clinical Trials Unit. The CVLP has been designed as a company and trial agnostic program so it can be flexible to the needs of multiple cancer vaccine trials in multiple cancer types. Methods: The CVLP aims to rapidly identify large numbers of cancer patients who could be eligible for trials to expedite evidence for the efficacy of vaccines across multiple types of cancer. To support the identification of participants their tissue samples are processed by a standardised, high quality, expanded pathway, incorporating elements of the NHS Genomic Medicine Service. The primary objective of the CVLP is to determine whether it is feasible to recruit cancer patients to a platform for personalised cancer vaccine trials, whether there is capacity for tumor samples to be analysed within a suitable time frame and if this results in acceptable participation in cancer vaccine clinical trials. Sponsored by NHS England the first trial incorporated within the CVLP is BioNTech BNT122-01 (NCT04486378) investigating the RO7198457 mRNA vaccine in patients with ctDNA-positive, resected Stage II/III colorectal cancer. Results: Between Sep 2023 and Dec 2024, 435 patients have consented to participate in the CVLP from 55 English sites, 96.4% of tissue samples were prepared in the required time frame for testing (average 2.5 days), of which 342 patients proceeded to referral to BNT122-01. We now estimate that approximately 60% of patients across England undergoing colorectal surgery have access to the trial through the CVLP resulting in the UK screening more than 3x the global average for BNT122-01 trial. The CVLP patient pathway from patient identification to entry into available clinical trials has been developed during the feasibility stage which now includes following the steps; i) patients identified by the clinical team managing their care and consented into CVLP; ii) blood and tissue samples (during surgery) collected; iii) samples sent to Cellular Pathology Genomic Centre and Genomic Laboratory Labs to carry out genomic sequencing; iv) sequencing data stored as part of NHS standard of care and the clinical liaison team pairs patients with available research trials. The CVLP has now progressed to onboarding further cancer vaccine trials in other cancer indications. Conclusions: CVLP has met its first feasibility endpoint of recruiting 300 patients and has progressed to onboarding further cancer vaccine trials. Citation Format: Gareth Griffiths, Victoria Goss, Nicole Keyworth, Daniel Muller, Sam Wilding, ","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"2 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB311: Dissecting and targeting EZH2’s non-canonical oncogenic activity in cancers","authors":"Arum Kim, G Greg Wang","doi":"10.1158/1538-7445.am2025-lb311","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-lb311","url":null,"abstract":"In many human cancer types, expression of Enhancer of Zeste Homolog 2 (EZH2) is well correlated with poorer outcomes. Furthermore, ∼20-25% of patients with diffuse large B-cell lymphoma (DLBCL) contain somatic mutation of EZH2 at the Tyr-646 residue within its catalytic SET domain, leading to EZH2 gain-of- function (GOF). Thus, EZH2 represents a prominent onco-target and small-molecule inhibitors targeting its enzymatic activity are under clinical evaluation, with some (i.e. tazemetostat) FDA-approved for the treatment of lymphoma and epithelial sarcoma. However, these EZH2 enzymatic inhibitors often face issues, such as ineffectiveness or resistance, and new treatment strategies targeting EZH2 are urgently needed. Traditionally, EZH2 is viewed as a catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which induces trimethylation of histone H3 lysine 27 (H3K27me3) for repressing the target gene expression such as tumor-suppressive and immune-related genes. We recently have shown that EZH2’s oncogenic functions go well beyond PRC2 and its enzymatic function for H3K27me3 deposition and has the new PRC2-independent activity (non-canonical) to sustain oncogenesis. We show that the non-canonical function of EZH2 partly rely on transcriptional activation domains (tADs) of EZH2, which physically interacts with oncogene (co)activators, to turn on the oncogenic signaling. Our unpublished data point to increased Myc signaling as well as cancer metabolism enhancement such as lipid metabolism. We demonstrate such non-canonical oncogenic activity of EZH2 in blood cancers (including DLBCL) and solid tumors, which may explain why the current enzymatic inhibitors of EZH2 have rather limited antitumor effect. To develop a more effective therapeutic strategy in which both the canonical and noncanonical activities of EZH2 can be targeted, we employ the Proteolysis Targeting Chimera (PROTAC) technology and developed novel EZH2-targeted PROTAC degraders. EZH2-targeted PROTACs induced the EZH2 degradation and target the aberrant gene expression from both canonical and non-canonical activities of EZH2, leading to more effective, more consistent growth inhibition in tumors, and to a much greater degree when compared to EZH2 methyltransferase inhibitors. Collectively, this work uncovers an unexplored function of EZH2 in sustaining tumorigenesis via enhancing non-canonical oncogenic signaling. Indeed, our data support EZH2 PROTAC to be an attractive therapeutic candidate for cancer treatments. Citation Format: Arum Kim, G Greg Wang. Dissecting and targeting EZH2’s non-canonical oncogenic activity in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB311.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"7 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB370: Tumor-infiltrating lymphocytes-derived CD8 clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma","authors":"Lucas C M Arruda, Julia Karbach, Dragan Kiselicki, Hans-Michael Altmannsberger, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Akin Atmaca, Elke Jäger","doi":"10.1158/1538-7445.am2025-lb370","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-lb370","url":null,"abstract":"Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown remarkable efficacy in treating melanoma and other \"hot\" tumors characterized by high tumor mutation burden (TMB), a biomarker increasingly recognized for predicting immunotherapy success in solid tumors. However, gliomas show no clear correlation between TMB and immunotherapy efficacy due to the immunosuppressive tumor microenvironment, defective antigen presentation and the restrictive blood-brain barrier, hindering the effectiveness of immunotherapy. We report the successful treatment of a rapidly progressing high-TMB glioblastoma patient with TILs expanded using a defined cytokine cocktail comprising IL-2, IL-15, and IL-21. The therapeutic regimen included lymphodepletion with a single dose of cyclophosphamide prior to TIL intravenous infusion followed by a single dose of IL-2 post-infusion. Remarkably, complete tumor regression was achieved following two TIL infusions administered two weeks apart. Sequential cranial MRI showed complete tumor remission 22 days after the second infusion, with biopsies of the tumor showing complete necrotic tissue transformation. The TIL products were enriched for CD8 T-cells with high IFNg production and CD107a expression. They exhibited dose-dependent, specific cytolytic activity against autologous tumor cell lines but not against an autologous EBV-transformed B-cell line, the allogeneic glioblastoma cell lines U-373 and DBTRG05, or the unrelated Daudi B-cell lymphoma cell line. After TIL infusion, peripheral blood T-cells exhibited TCR downregulation, indicating activation, alongside with increased numbers of effector memory CD8 T-cells and CD4 Th1 and Th17 subtypes, while terminally differentiated CD8 T-cells decreased. A surge in serum IL-6 and sIL-2R levels was seen after each TIL infusion, confirming the strong systemic T-cell activation. Hematological analyses revealed persistent lymphopenia despite the use of reduced conditioning regimen. Surgical tumor samples collected before and after TIL infusions were analyzed by whole-exome sequencing (WES), RNA-seq and T-cell receptor (TCR) next-generation sequencing. WES revealed a high mutation burden (>10/Mb) across all samples, including mutations on EGFR, TP53 and BRCA1/2. Transcriptomic analysis of post-infusion tumor biopsies demonstrated enhanced expression of genes associated with immunological synapse formation and T-cell effector function, in line with the observed clinical response. TCR sequencing demonstrated that TIL-derived CD8 T-cells effectively infiltrated the tumor tissue and were strongly associated with tumor clearance. Hyperexpanded clonotypes within the tumor indicated robust TIL expansion in vivo, highlighting the significant contribution of TIL-derived CD8 T-cell proliferation to tumor control. CD4 T-cells, despite presenting greater TCR diversity than CD8 T-cells within the infused product, showed limited infiltration. This case highlights the potential o","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"72 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract SY14-03: Exploiting dysregulated ribosomal homeostasis in chromosome 9p21.3 deleted cancers and microsatellite unstable cancers","authors":"Patricia Borck, Isabella Boyle, Kristina Jankovic, Nolan Bick, Kyla Foster, Anthony Lau, Lucy Parker-Burns, Daniel Lubicki, Ashir Borah, Nicholas Lofaso, Sohani Das Sharma, Riya V. Kishen, Joshua Dempster, Francisca Vazquez, Edmond M. Chan","doi":"10.1158/1538-7445.am2025-sy14-03","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-sy14-03","url":null,"abstract":"Synthetic lethality, a phenomenon in which alterations in two or more genes together induce cell death while changes in either gene alone do not, provides a promising approach for cancer treatment. Indeed, various inhibitors targeting synthetic lethal interactions are approved by the Food and Drug Administration or in clinical trials. Seeking to nominate additional synthetic lethal targets, we analyzed large-scale CRISPR knockout screening data and identified Pelota mRNA surveillance and ribosome rescue factor (PELO) as a promising therapeutic target for two independent and frequently observed molecular subtypes of cancer: biallelic deletion of chromosomal region 9p21.3 (9p21.3-/-) and microsatellite instability-high (MSI-H). Homozygous deletion of chromosomal region 9p21.3 is one of the most frequently observed somatic copy number alterations in human cancers, occurring in approximately 15% of all cancers. Many 9p21.3-/- cancers are associated with poor clinical outcomes including subsets of glioblastoma, mesothelioma, urothelial, pancreatic, esophageal, and non-small cell lung cancers. The primary driver of 9p21.3-/- is thought to be loss of the tumor suppressor cyclin-dependent kinase inhibitor 2A. Additionally, studies have linked the loss of the interferon gene cluster on 9p21.3 to immune evasion and primary resistance to immune checkpoint inhibitors. Extensive deletions of chromosomal regions can provide opportunities for cancer treatment. For instance, PRMT5 and MAT2A were found to be promising targets in 9p21.3-/- cancers due to synthetic lethal interactions with deletions of the 9p21.3 gene methylthioadenosine phosphorylase. While clinical trials are underway examining PRMT5 and MAT2A inhibitors, the frequency and poor outcomes of many 9p21.3−/− cancers underscores the urgent need for additional therapies to treat this diverse group of cancers. Using large-scale functional genomic datasets, we identified PELO as the top preferential dependency in 9p21.3-/- cell lines. We also observed that some cell lines with intact 9p21.3 (9p21.3+) were dependent on PELO for survival. Examining other genomic features, we found that these cells were characterized as MSI-H, a hypermutable state observed in subsets of colon, endometrial, gastric, and ovarian cancers. Indeed, when we compared 9p21.3+/MSI-H and 9p21.3+/microsatellite stable (MSS) cell lines, we found that PELO scored as a strong preferential dependency in MSI-H cell lines, second only to the previously described synthetic lethal target Werner helicase (WRN). To validate these findings, we interrogated the viability effects of PELO knockdown across a panel of cell lines representing 9p21.3+/MSS, 9p21.3-/-/MSS, or 9p21.3+/MSI-H. CRISPR interference (CRISPRi)-mediated PELO knockdown with three distinct guide RNAs impaired the viability of 9p21.3-/-/MSS cell lines and 9p21.3+/MSI-H cell lines, but not 9p21.3+/MSS cell lines. We also sought to validate PELO dependency in tumor organoid models fo","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"15 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract CT052: A highly selective, brain-penetrant and overcoming G2032R resistance ROS1 inhibitor JYP0322 in NSCLC patients with ROS1 fusion","authors":"Hongyun Zhao, Yanqiu Zhao, Yuxiang Ma, Yan Zhang, Zhangzhou Huang, Ying Cheng, Zhengbo Song, Yongzhong Luo, Juan Li, Wei Wei, Yaling Qi, Binyan Xia, Yuexia Zeng, Jing Lv, Li Zhang","doi":"10.1158/1538-7445.am2025-ct052","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-ct052","url":null,"abstract":"Background: JYP0322 is a potent, brain-penetrant and highly selective ROS1 inhibitor, demonstrating over 100-fold selectivity for ROS1 compared to TRKA and sub-nanomolar potency against the ROS1 G2032R resistance mutation. JYP0322 is designed to simultaneously address the key clinical challenges including ROS1 resistance mutations, tumor brain metastases while avoiding the off-target neurotoxicity associated with TRK inhibition. Method: The Phase I study (NCT06128148) was designed to evaluate safety, pharmacokinetics (PK), and preliminary clinical efficacy in patients with locally advanced or metastatic ROS1+NSCLC, including both ROS1 TKI pre-treated patients as well as TKI naïve patients. Response was assessed by investigators according to RECIST V1.1. Results: As of December 10, 2024, dose escalation study was conducted across 7 dose levels: 50mg qd, 100mg qd, 200mg qd, 100mg bid, 150mg bid, 200mg bid, 150mg tid and dose expansion stage is ongoing at doses of 100mg bid, 150mg bid and 150mg tid. A total of 73 NSCLC patients were enrolled. No dose-limiting toxicities were observed. The most frequently reported treatment related adverse events (TRAE) were low grade including weight gains (32.9%), hyperglyceridemia (31.5%), hypercholesteremia (26%), and AST elevation (21.9%). Grade 3-5 TRAE occurred in 12.3% patients. Only low grade neurotoxicities (6.8%) occurred. Among 58 efficacy evaluable patients, objective response rates (ORRs) were 85.7% (12/14) for ROS1 TKI naive, 54.5% (12/22) for patients previously received ≥2L systemic therapy and ≥1 prior ROS1 TKIs including 19 patients pre-treated with 2 to 4 ROS1 TKIs (Table). In ROS1 G2032R mutant cancers, ORR was 71.4% (5/7) with 3 patients pre-treated with Lorlatinib. In patients with measurable brain metastasis at baseline, intracranial ORR was 33.3% (2/6) and intracranial DCR was 83.3%. JYP0322 showed significantly brain penetration ability with the brain to plasma ration 1.20. Enrollment in the dose expansion stage is ongoing. Conclusions: JYP0322 had a favorable safety profile with a low incidence of neurotoxicities. It showed highly promising anti-tumor effects in patients with ROS1+NSCLC including both TKI-naïve and TKI pre-treated patients, as well as those with TKI-heavily treated, brain metastases, or harboring ROS1 G2032R mutation. Citation Format: Hongyun Zhao, Yanqiu Zhao, Yuxiang Ma, Yan Zhang, Zhangzhou Huang, Ying Cheng, Zhengbo Song, Yongzhong Luo, Juan Li, Wei Wei, Yaling Qi, Binyan Xia, Yuexia Zeng, Jing Lv, Li Zhang. A highly selective, brain-penetrant and overcoming G2032R resistance ROS1 inhibitor JYP0322 in NSCLC patients with ROS1 fusion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr CT052.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"29 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB363: Multi-mechanism human B7H3 CAR-T effectively overcome tumor microenvironment resistance in treatment of solid tumors","authors":"Keming Zhang, Katie O'Callaghan, Ning Jiang, Ryan Feng, Tony Ruan, Jenna Nguyen, Sam Hassan, Kehao Zhao, Yan Chen","doi":"10.1158/1538-7445.am2025-lb363","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-lb363","url":null,"abstract":"Background: Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematological cancers, but its application for solid tumors remains limited. Tumor antigen heterogeneity, insufficient T cell trafficking, and immunosuppressive tumor microenvironment (TME) are the key challenges of resistance. Several approaches such as engineering CAR-T to express chemokines to support trafficking to tumors, expression of checkpoint inhibitor pathway blockers, and modification of T cell metabolism to overcome TME have been reported. To deliver an integrated solution, Elpis has developed a B7H3 CAR-T armored with a precision engineered multi-mechanism armor to simultaneously overcome multiple TME resistant mechanisms. B7H3 is overexpressed on a wide range of solid tumors, including skin, pancreatic, lung, breast, colon, kidney and other cancers. Importantly, B7H3 is highly expressed on differentiated malignant cells and cancer-initiating cells, with limited B7H3 heterogeneity, and low level of expression on normal tissues. Methods: We have discovered a panel of human anti-B7H3 and anti-PD-L1 single-chain variable fragments (scFvs) with a broad affinity range and extensive epitope coverage. This was achieved using our proprietary mRNADis™ mRNA display technology, combined with live-cell selection from proprietary human B cell libraries. To enhance therapeutic efficacy, we engineered a multi-mechanism armor by fusing an anti-PD-L1 scFv with a fine-tuned IL-2 variant, optimized via our mSCAFold™ cytokine engineering platform. We have developed EPC-002, a next-generation fully human anti-B7H3 armored CAR-T, aiming to treat a broad range of solid tumors with enhanced efficacy, favorable safety, and improved persistence. EPC-002 secretes a multi-mechanism armor, designed to augment the immune cell function in the TME. The anti-PD-L1 scFv blocks inhibitory checkpoint signaling, while the engineered IL-2 suppresses Treg activation, activates T central memory (TCM) cells, drives the proliferation of CAR-T, and improves the anti-tumor immunity of the CAR-T therapy. Results: EPC-002 demonstrated robust cancer cell engagement, leading to effective cytotoxic killing of cancer cells. In A375 melanoma mouse model, as low as 3x105 CAR-T cells mediated complete tumor regression. When these mice were rechallenged with Capan-2, a pancreatic cancer line expressing B7H3, these treated mice resisted new Capan-2 tumor growth and persisted through 110 days of treatment course. Pharmacodynamic studies demonstrated robust CAR-T and bystander T cell infiltration. The expanded TCM CAR-T phenotype was observed from PBMCs and splenocytes, enhances anti-tumor activity while improving CAR-T cell persistence. Conclusion: EPC-002 is a promising candidate that potentially enhances anti-tumor activity, reduces multiple immunosuppression mechanisms within the TME. These novel mechanisms could potentially translate into durable clinical efficacy for treating solid tumors. ","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"33 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB212: Efficacy and safety of JS015 (an anti-dickkopf-1 antibody) in combination with standard of care in patients with gastrointestinal cancers","authors":"Yong Gao, Ming Quan, Jianwei Yang, Xinjun Liang, Huiting Xu, Tao Zhang, Mingjun Zhang, Funan Liu, Lin Shen, Jingdong Zhang, Caixia Wang, Yiye Wan, Weiwei Wang, Yuanyuan Yu, Jing Xu, Chengbo Jia, Zexi Li, Huajun Li, Jin Li","doi":"10.1158/1538-7445.am2025-lb212","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-lb212","url":null,"abstract":"Background: Dickkopf-1 (DDK1) has been identified as an antagonist of the Wnt pathway, which plays a complex role in tumor development and metastasis. DDK1 inhibitors have been clinically studied and showed promising anti-tumor activities in gastrointestinal carcinoma. Here, we report the preliminary efficacy and safety data of JS015 in combination with standard of care in gastrointestinal patients from JS015-002 study (NCT06139211) and 2 IITs (ChiCTR2400091501 and ChiCTR2400088962) conducted in China. Methods: Patients with colorectal cancer that were not systematically treated (1L-CRC) or who had progressed after treatment with fluorouracil-based regimen (2L-CRC) received JS015 600 mg (intravenously) plus bevacizumab and chemotherapy, once every 2 weeks or 3 weeks, depending on chemotherapy schedules. Patients with gastric cancer that were not systematically treated (1L-GC) received JS015 600 mg plus toripalimab and chemotherapy, once every 3 weeks. The primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Results: As of the data cutoff (December 25, 2024), 36 patients with 2L-CRC, 6 patients with 1L-CRC, and 8 patients with 1L-GC were enrolled, with a respective median follow-up of 1.22, 1.41, and 1.38 months. In the efficacy analysis, among the 17 patients with 2L-CRC, 7 patients achieved a partial response (PR) and 8 patients had a stable disease (SD), producing an ORR of 41.2% (95% CI: 18.4%, 67.1%) and a DCR of 88.2% (95% CI: 63.6%, 98.5%); Among the 4 patients with 1L-CRC, there were 3 patients with PR and 1 patient with SD, producing an ORR of 75.0% (95% CI: 19.4%, 99.4%) and a DCR of 100.0% (95% CI: 39.8%, 100.0%); Among the 5 patients with 1L-GC, there were 3 patients with PR and 2 patients SD, resulting an ORR of 60.0% (95% CI: 14.7%, 94.7%) and a DCR of 100.0% (95% CI: 47.8%, 100.0%). Overall, the incidence of treatment-related adverse events (TRAEs) was 64.0% among those patients with CRC and GC. TRAEs were predominantly grade 1 or 2, and no grade 5 adverse events were reported. TRAEs of grade 3 or higher only occurred in 8 patients (8/50, 16.0%) among patients with 2L-CRC, including neutrophil count decreased (5/50, 10%), white blood cell count decreased (2/50, 4%), and aspartate aminotransferase increased, diarrhoea, and liver injury (1/50, 2.0% for each). Conclusion: JS015 combination therapy showed encouraging anti-tumor activities in patients with CRC and GC, with a favorable safety profile, supporting further investigations in a large population of patients with gastrointestinal carcinomas. Citation Format: Yong Gao, Ming Quan, Jianwei Yang, Xinjun Liang, Huiting Xu, Tao Zhang, Mingjun Zhang, Funan Liu, Lin Shen, Jingdong Zhang, Caixia Wang, Yiye Wan, Weiwei Wang, Yuanyuan Yu, Jing Xu, Chengbo Jia, Zexi Li, Huajun Li, Jin Li. Efficacy and safety of JS015 (an anti-dickkopf-1 antibody) in combination with standard of care in patients with gastrointestinal cance","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"42 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB309: Differential DNA methylation analysis and functional insights in luminal A and triple-negative breast cancer using FFPE samples","authors":"Yangbo Sun, Khyobeni Mozhui, Jay H. Fowke, Saunak Sen, Karen C. Johnson","doi":"10.1158/1538-7445.am2025-lb309","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-lb309","url":null,"abstract":"Background: Epigenetic modifications, such as DNA methylation, play a critical role in breast cancer heterogeneity, influencing tumor progression and therapeutic responses. This study investigates differential methylation patterns between luminal A (LumA) and triple-negative breast cancer (TNBC) subtypes using formalin-fixed, paraffin-embedded (FFPE) samples. Functional insights are derived through gene ontology and pathway analyses to understand subtype-specific epigenetic mechanisms. Methods: Genome-wide methylation profiling was performed on FFPE samples of LumA (n=3) and TNBC (n=5) cases using the Illumina Infinium EPIC array. Differentially methylated CpG sites were identified, and gene ontology analysis and pathway enrichment analyses were conducted on genes annotated to differentially methylated CpG sites to identify biological processes and pathways driving subtype differences. Results: Among the 937,690 original probes, 319,514 probes failed in at least one sample and were excluded from further analysis, thus, 618,176 probes were kept for analysis. A total of 28,801 differentially methylated CpG sites were identified between LumA and TNBC cases, with a threshold on methylation differences of 10%. A total of 12,772 genes were associated with the 28,801 significant differentially methylated probes identified between LumA and TNBC. Key enriched gene oncology terms included \"small GTPase-mediated signal transduction \", \" regulation of trans-synaptic signaling”, and “actin filament organization”, highlighting subtype-specific epigenetic regulation of tumor biology. Pathway analysis revealed significant enrichment of pathways such as \"RHO GTPase cycle\" and “RAC1 GTPase cycle” in TNBC, consistent with their distinct tumor microenvironments. Conclusions: This study highlights distinct methylation patterns in LumA and TNBC subtypes, reflecting their divergent biological and clinical behaviors. The identified pathways provide insights into potential therapeutic targets and biomarkers for precision oncology and the ability to obtain DNA methylation data from formalin-fixed, paraffin-embedded (FFPE) samples. Future work will validate these findings in larger, independent cohorts and explore their clinical applicability. Citation Format: Yangbo Sun, Khyobeni Mozhui, Jay H. Fowke, Saunak Sen, Karen C. Johnson. Differential DNA methylation analysis and functional insights in luminal A and triple-negative breast cancer using FFPE samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2): nr LB309.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"17 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract CT149: A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor, in patients with advanced or metastatic solid tumors","authors":"Soumit Basu, Binaish Khan, Francis Payumo, E Gabriela Chiorean, Zhubin Gahvari, J Randolph Hecht, Michael Hurwitz, Rom Leidner, Heinz-Josef Lenz, Meredith Pelster, Salman Punekar, Adam Schoenfeld, Dan Zhao, Dirk Nagorsen","doi":"10.1158/1538-7445.am2025-ct149","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-ct149","url":null,"abstract":"Background: Activating mutations in KRAS (including KRAS G12V) are well-described oncogenic drivers in solid tumors, conferring poor prognosis to patients due to a lack of effective therapies for cancers with such KRAS driver mutations. T cell receptor (TCR)-T cell therapies targeting mutant KRAS have demonstrated proof of concept in the clinic, but duration of response remains a challenge.1,2 AFNT-211 represents a novel strategy to address the immunosuppressive tumor microenvironment and improve response rate as well as duration of response in solid tumors. Methods: This ongoing Phase 1, first-in-human, multicenter, open-label study of AFNT-211evaluates safety/tolerability, as well as its clinical (antitumor) activity with the goal to identify an optimal biological dose (OBD) and recommended Phase 2 dose (RP2D) in patients with HLA 11:01 who suffer from cancers driven by the KRAS G12V mutation. The initial dose escalation part of the study follows Bayesian optimal interval Phase 1/2 (BOIN12), which quantifies the desirability of a dose in terms of toxicity-efficacy tradeoff and adaptively allocates patients to the dose with the highest estimated desirability. After determination of OBD and RP2D based on the totality of the risk/benefit assessment and the BOIN12, the study is planned to proceed to the dose expansion phase which will consist of cohorts enrolling patients with tumors with high KRAS G12V prevalence (pancreatic cancer, colorectal cancer, non small cell lung cancer) as well as a tumor agnostic arm (any other solid tumor with KRAS G12V).This study has started enrolling patients ≥ 18 years old positive for HLA-A*11:01-positivewithadvanced/metastatic solid tumors harboring a KRAS G12V mutation who have proven intolerant of or refractory to at least one prior standard of care systemic therapy. Patients undergo leukapheresis to collect T cells for the manufacturing of AFNT-211, and receive lymphodepleting chemotherapy prior infusion of their autologous AFNT-211 product. Following this, patients proceed into a 28-day dose-limiting toxicity observation period (during dose escalation) followed by a post-treatment follow-up period for 24 months/until disease progression. The study is open for recruitment in the United States (NCT06105021). References: 1.Cook J, Melloni G, Gulhan D, et al. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun 2021;12:1808.2.Hofmann MH, Gerlach D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12:924-937. Citation Format: Soumit Basu, Binaish Khan, Francis Payumo, E Gabriela Chiorean, Zhubin Gahvari, J Randolph Hecht, Michael Hurwitz, Rom Leidner, Heinz-Josef Lenz, Meredith Pelster, Salman Punekar, Adam Schoenfeld, Dan Zhao, Dirk Nagorsen. A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β corec","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"219 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract CT161: Dose-optimization using exposure response analysis in AFM24 (in monotherapy and with atezolizumab) in patients with advanced/metastatic non-small cell lung cancer","authors":"Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Schütz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko","doi":"10.1158/1538-7445.am2025-ct161","DOIUrl":"https://doi.org/10.1158/1538-7445.am2025-ct161","url":null,"abstract":"Background: AFM24 is a tetravalent, bispecific ICE® that binds CD16A on NK cells and macrophages and EGFR on solid tumors, redirecting and enhancing the innate and possibly the adaptive immune response towards EGFR+ tumors. AFM24 has been administered weekly intravenously (IV) (dose escalation up to 720mg in single agent and 480mg in combination and deemed safe) to patients (pts) in phase 1/2a studies AFM24-101 as monotherapy and in AFM24-102 in combination with 840 mg atezolizumab IV fortnightly. Objective and Methods: A post-hoc exposure response analysis was performed on pts with non-small cell lung cancer treated with AFM24 480mg as a monotherapy or in combination with atezolizumab (N=44). A mean trough value per patient (Tpat) was calculated using all trough values from Day 22 onwards. Pts were split into LOW (Tpat ≤ Median) and HIGH (Tpat > Median) groups and the association between exposure and clinical outcome was assessed. To confirm such correlations a sensitivity analysis using quartiles of exposure was conducted. Results: Overall, 44 pts were included in this analysis with the median trough level (cut point of High (N=22) vs. Low (N=22)) being 97642 ng/mL. Baseline characteristics were generally balanced; pts in the High group had more median lines of prior treatment (3 vs 2) and pts in the LOW group showed higher mean baseline LDH levels (365 U/L vs 202 U/L). Body mass index and actual received mean dose intensity were similar. Preliminary assessment of efficacy demonstrated an apparent better response in pts in the HIGH group throughout all endpoints assessed. Patients in the HIGH group showed a significantly higher Objective Response rate (36.4% vs 4.6% [p = 0.021]), Disease Control Rate (86.4% vs 36.4% [p=0.002]), median Progression Free Survival ([PFS] 7.3 vs 1.9 months [p-value: 0.003)] and Overall Survival (not estimable vs 16 months). An analysis by quartiles confirmed the exposure response correlation with ORR of 0%, 9.1%, 18.2% and 54.6% from the lowest to the highest quartile. PK data showed very early separation between high and low exposure pts starting at the second infusion. In line with the early separation, pts with low exposure had a very high risk of early tumor progression (59% vs 14% PD in the first 2 months). A subgroup analysis in pts treated with AFM24 plus atezolizumab (26 pts) confirmed the findings with 46.2% ORR for high and 7.7% for low exposure. Higher exposure was not associated with increased frequency or severity of AEs. Conclusions: The data show a strong correlation between exposure and clinical outcome with a significantly increased risk for early tumor progression in the low exposure group. PK modeling suggests that a dose of 720mg AFM24 weekly will result in exposure levels exceeding the cutoff for the high exposure group as early as week 2. The 720mg dose, which has already been established as safe in the phase 1 trial, will be used in future AFM24 studies. Citation Format: Anthony El-Khou","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"3 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}